Semaglutide Lowers Blood Pressure by 3 mmHg in Obese People — More at Higher Doses and in Non-Diabetics | Research

The takeaway

A meta-analysis of 22 RCTs involving 15,347 participants found semaglutide significantly reduces both systolic (-2.9 mmHg) and diastolic (-0.86 mmHg) blood pressure, with stronger effects at 2.4 mg dose and in non-diabetic populations.

-5.02 mmHg systolic in non-diabetic obese patients
Non-diabetic obese people showed the largest blood pressure drop with semaglutide — nearly double the effect seen in diabetic patients — suggesting blood pressure benefits beyond metabolic improvement.

What the researchers found

Across 22 RCTs (15,347 participants), semaglutide significantly reduced systolic blood pressure (MD -2.90 mmHg, 95% CI -3.70 to -2.11, P<0.01) and diastolic blood pressure (MD -0.86 mmHg, 95% CI -1.34 to -0.38, P<0.01). Subgroup analysis: non-diabetic populations showed greater reductions (SBP -5.02 mmHg, DBP -1.96 mmHg) versus diabetic populations (SBP -1.87 mmHg, DBP -0.43 mmHg). Higher dose (2.4 mg) significantly lowered SBP by 4.31 mmHg and DBP by 1.84 mmHg. Sensitivity analysis confirmed robust results.

Why it matters

Hypertension is the leading modifiable risk factor for cardiovascular disease and stroke. Finding that semaglutide reduces blood pressure — especially at the higher 2.4 mg obesity dose — adds another reason to prescribe it for obese patients who often have multiple cardiovascular risk factors. The greater effect in non-diabetic populations suggests the blood pressure benefit isn't just from improved metabolic health but may involve direct cardiovascular mechanisms.

How the study worked

Systematic review and meta-analysis of randomized controlled trials searching PubMed, Embase, Cochrane Library, and Web of Science through October 2024. Included 22 studies with 15,347 participants evaluating semaglutide's effect on blood pressure in obese populations. Statistical analysis used Stata with mean differences and 95% confidence intervals. Subgroup analyses by diabetes status and semaglutide dose. Egger's test assessed publication bias. Sensitivity analysis evaluated result stability.

What this study cannot tell us

Heterogeneity was present in some subgroup analyses, particularly at the 2.4 mg dose level. The blood pressure reductions, while statistically significant, are modest in absolute terms (2.9 mmHg systolic). Whether these reductions are independent of weight loss is unclear — weight reduction alone would be expected to lower blood pressure. The meta-analysis combined studies with different durations, populations, and semaglutide formulations (subcutaneous and oral). Individual patient data were not available for more granular subgroup analyses.

How to read the evidence

Meta-analysis of 22 randomized controlled trials with over 15,000 participants represents high-quality evidence synthesis. Sensitivity analysis confirmed robustness. However, heterogeneity in some analyses and the inability to separate weight-dependent from weight-independent mechanisms are limitations.

When this study was published

Published in 2025 with literature through October 2024, this is the most comprehensive and current meta-analysis of semaglutide's blood pressure effects.

The bigger picture

This meta-analysis adds blood pressure reduction to semaglutide's portfolio of cardiovascular benefits (which already includes MACE reduction, heart failure improvement, and kidney protection). A 5 mmHg reduction in systolic blood pressure has been shown to reduce stroke risk by about 14% and coronary heart disease by 9% at the population level. For obese patients already taking semaglutide for weight loss, this blood pressure benefit comes essentially 'for free' — no additional medication needed.

Questions still open

How much of semaglutide's blood pressure reduction is from weight loss versus a direct vascular or renal mechanism?
Could semaglutide reduce the need for antihypertensive medications in obese patients with mild hypertension?
Why is the blood pressure effect stronger in non-diabetic populations — does diabetes itself blunt the response?

Common questions

Does semaglutide lower blood pressure?

Yes — this meta-analysis of 22 clinical trials with over 15,000 participants confirms that semaglutide significantly lowers both systolic and diastolic blood pressure in obese people. The effect is larger at higher doses (4.3 mmHg drop at 2.4 mg) and surprisingly stronger in non-diabetic obese people (5 mmHg drop) than in those with diabetes.

Could semaglutide replace blood pressure medication?

While a 3-5 mmHg blood pressure reduction is meaningful (it reduces cardiovascular risk), it's typically not enough to replace blood pressure medication entirely for people with moderate-to-severe hypertension. However, for people with mildly elevated blood pressure who are also obese, semaglutide's blood pressure benefit combined with weight loss could be sufficient — and it might allow reducing the number of BP medications needed.

Read the original research

Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 25(5), 655-665

View on PubMed ↗Publisher’s paper ↗

Citation

Li, Yihan; Xue, Kefan; Hu, Rui; Hu, Xiao; Guo, Ran; Guo, Hongxia; Li, Gang. (2025). Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.. American journal of cardiovascular drugs : drugs, devices, and other interventions, 25(5), 655-665. https://doi.org/10.1007/s40256-025-00738-9